Core Insights - The stock of Nearshore Protein experienced a decline of 1.46% on October 13, with a trading volume of 13.18 million yuan [1] - The company reported a net financing outflow of 2.93 million yuan on the same day, with total financing and securities lending balance at 69.15 million yuan [1] Financing and Trading Activity - On October 13, Nearshore Protein had a financing buy-in of 1.55 million yuan, while the current financing balance is 69.15 million yuan, accounting for 5.05% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low position [1] - There were no shares sold or repaid in the securities lending market on October 13, with the lending balance also at zero, suggesting a high position relative to the 90th percentile level over the past year [1] Company Overview - Nearshore Protein, established on September 7, 2009, and listed on September 29, 2022, is located in Suzhou, Jiangsu Province [1] - The company's main business includes the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with related technical services [1] - The revenue composition is as follows: target and factor proteins 58.04%, enzymes and reagents 25.63%, CRO services 11.87%, recombinant antibodies 2.67%, and others 1.79% [1] Financial Performance - For the period from January to June 2025, Nearshore Protein achieved a revenue of 72.09 million yuan, representing a year-on-year growth of 20.85%, while the net profit attributable to the parent company was -24.22 million yuan, a decrease of 172% year-on-year [2] - Since its A-share listing, the company has distributed a total of 70.18 million yuan in dividends [3] Shareholder Information - As of August 20, the number of shareholders for Nearshore Protein was 6,459, a decrease of 4.41% from the previous period, with an average of 5,058 circulating shares per person, an increase of 4.61% [2] - As of June 30, 2025, notable institutional shareholders include Huashang LeXiang Flexible Allocation Mixed A, which increased its holdings by 41,500 shares, and several new institutional shareholders have entered the top ten list [3]

Group 1 - The National Development and Reform Commission will hold a press conference to discuss the achievements of grain circulation reform during the 14th Five-Year Plan period [1] - Microsoft has stopped providing security updates and technical support for Windows 10, increasing the risk of cyberattacks for users [2] - A total of 2.15 billion yuan worth of restricted shares will be unlocked today, with major contributions from Zhaoyi Innovation and Dingyang Technology [3] Group 2 - 15 companies have disclosed their stock repurchase progress, with significant amounts proposed by several firms, including China Merchants Industry and Jiuan Medical [4] - Economic data such as the Eurozone ZEW Economic Sentiment Index and the UK's unemployment rate for September will be released [5]

Group 1 - On October 14, 15 companies announced 15 stock repurchase updates, with 6 companies disclosing repurchase plans for the first time, 3 plans approved by shareholders, 4 companies reporting implementation progress, and 2 completing their repurchase plans [1] - The highest proposed repurchase amounts from newly disclosed plans are from COSCO Shipping Holdings at 1.498 billion, Jiuan Medical at 600 million, and China National Chemical Engineering at 100 million [1] - Companies that received shareholder approval for their repurchase plans include Nearshore Protein with a proposed repurchase of up to 20 million, Haoshanghao at 266,400, and Runbei Aerospace Technology at 227,100 [1] Group 2 - The highest amounts repurchased from companies reporting implementation progress are from Ruikang Pharmaceutical at 69.3892 million, Qianwei Central Kitchen at 49.9827 million, and Baiwei Storage at 39.9905 million [1] - Completed repurchases include China Merchants Port at 389 million and Rongxin Culture at 21.999 million [2] - As of October 14, a total of 1,614 repurchase plans have been completed this year, involving 1,226 companies, with 312 companies having completed repurchases exceeding 100 million [2]

格隆汇10月13日丨近岸蛋白(688137.SH)公布，2025年10月13日，公司收到股东菏泽乔贝和上海普近发 来的《关于股份减持结果的告知函》，本次减持股东通过集中竞价交易方式合计减持公司股份31.41万 股，占公司总股本比例为0.4476%。本次减持计划已实施完毕。 ...

2025年7月9日，近岸蛋白披露股东拟通过集中竞价、大宗交易、协议转让等方式合计减持不超过42.51 万股，减持比例合计不超过公司股份总数的0.6058%。 苏州近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"）于2025年10月14日发布股东减持股份结果公 告，披露了股东菏泽乔贝京煦创业投资合伙企业（有限合伙）（以下简称"菏泽乔贝"）和上海普近科技 发展合伙企业（有限合伙）（以下简称"上海普近"）的减持情况。 减持前持股情况 减持计划实施前，菏泽乔贝持有近岸蛋白79.53万股股份，占公司总股本比例为1.1333%；上海普近持有 公司26.32万股股份，占公司总股本比例为0.3750%。二者均为5%以下股东，且无一致行动人，持股均 来源于IPO前取得。 减持计划及实施结果 截至2025年10月13日，本次减持股东通过集中竞价交易方式合计减持公司股份31.41万股，占公司总股 本比例为0.4476%，减持计划已实施完毕。具体来看： -菏泽乔贝：在2025年7月14日至2025年10月13日 期间，通过集中竞价减持16.20万股，减持价格区间为41.44 - 50.68元/股，减持总金额784.91万元。减持 完 ...

每经AI快讯，近岸蛋白（SH 688137，收盘价：41.9元）10月13日晚间发布公告称，2025年10月13日， 公司收到股东发来的《关于股份减持结果的告知函》，本次菏泽乔贝、上海普近通过集中竞价交易方式 合计减持公司股份约31万股，占公司总股本比例为0.4476%。本次减持计划已实施完毕。 截至发稿，近岸蛋白市值为29亿元。 每经头条（nbdtoutiao）——AI技术滥用调查：明星可被"一键换装"，"擦边"内容成流量密码，技术防 线为何形同虚设？ （记者 曾健辉） 2024年1至12月份，近岸蛋白的营业收入构成为：生命科学基础研究占比43.35%，体外诊断占比 18.64%，生物药占比16.2%，其他业务占比12.54%，mRNA疫苗药物占比9.27%。 ...

Core Viewpoint - Suzhou Nearshore Protein Technology Co., Ltd. has announced an extension of its share repurchase plan by six months, now set to conclude on April 13, 2026, while other aspects of the repurchase plan remain unchanged [1] Summary by Sections Share Repurchase Plan Overview - On September 26, 2024, the company held its second board meeting and subsequently approved a share repurchase plan during the third extraordinary general meeting of shareholders on October 15, 2024. The plan involves using self-owned funds to repurchase a portion of its issued ordinary shares (A-shares) through centralized bidding on the Shanghai Stock Exchange. The repurchase price will not exceed 30.68 yuan per share, with a total repurchase fund of no less than 10 million yuan and no more than 20 million yuan, to be completed within 12 months from the approval date [2] Reasons for Extending the Repurchase Period - Since the approval of the repurchase plan, the company has actively pursued the repurchase. However, due to various factors such as market conditions, stock price fluctuations, funding arrangements, and trading windows, it is anticipated that the repurchase plan cannot be completed within the original timeframe. The company has decided to extend the repurchase period to maintain long-term sustainable operations and protect the long-term interests of all shareholders [3] Impact on the Company and Decision-Making Process - The extension of the share repurchase period will not have a significant impact on the company's financial status, production operations, or future development. It also does not harm the interests of the company or its shareholders, particularly minority shareholders. On October 13, 2025, the company convened its second board meeting to approve the extension of the repurchase period. Since the third extraordinary general meeting of shareholders in 2024 had already authorized the board to handle related matters, no further shareholder approval is required for this extension [4]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-040 苏州近岸蛋白质科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 | 股东名称 | 菏泽乔贝 | | | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 √否 | 一、减持主体减持前基本情况 1 | | 直接持股 5%以上股东 | □是 | √否 | | --- | --- | --- | --- | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：5%以下股东 | | | | 持股数量 | 795,292股 | | | | 持股比例 | 1.1333% | | | | 当前持股股份来源 | IPO 前取得：795,292股 | | | 股东名称 上海普近 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 □是 √否 董事、监事和高级管理人员 □是 √否 其他：5%以下股东 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-041 苏州近岸蛋白质科技股份有限公司 关于延长股份回购实施期限的公告 自 2024 年 10 月 15 日召开 2024 年第三次临时股东大会审议通过回购股份方 案以来，公司积极推动回购股份方案的实施。在实施回购期间，受市场行情、公 司股价波动、资金计划安排、交易窗口期等多重因素的综合影响，预计在原定的 回购期限内，无法完成回购计划。根据《上市公司股份回购规则》《上海证券交 易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司综合考虑行 业竞争态势、公司经营现状以及未来的战略发展及资金使用情况等多重因素后， 从维持公司长期可持续经营能力，维护公司全体股东长远利益等角度出发，公司 拟将原回购方案实施期限延长 6 个月，公司股份回购实施截止日期延期至 2026 年 4 月 13 日止。除回购实施期限延长外，回购方案的其他内容未发生变化。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公 ...

南财智讯10月13日电，近岸蛋白公告，公司股东荷泽乔贝和上海普近在2025年7月14日至2025年10月13 日期间，通过集中竞价交易方式合计减持公司股份31.41万股，占公司总股本比例为0.45%，减持总金额 为1531.55万元。荷泽乔贝减持16.20万股，减持比例为0.23%，减持后持股比例为0.90%；上海普近减持 15.22万股，减持比例为0.22%，减持后持股比例为0.16%。此次减持计划已实施完毕。 ...